Why Is Mirabegron XR So Hard to Find? [Explained for 2026]

If you've been prescribed Mirabegron XR (brand name: Myrbetriq) for overactive bladder and found yourself calling pharmacy after pharmacy in 2026, you are not alone. Patients across the country are running into roadblocks — some caused by ongoing legal battles over generic manufacturing rights, others by sweeping insurance policy changes that took effect in late 2025. This guide breaks down exactly why Mirabegron XR is hard to find right now and what you can do about it.

What Is Mirabegron XR?

Mirabegron XR is an extended-release tablet used to treat overactive bladder (OAB) — a condition marked by urgent and frequent urination, often with urge incontinence. Unlike older OAB drugs that work by blocking muscarinic receptors throughout the body (causing dry mouth, constipation, and cognitive side effects), Mirabegron XR works by activating beta-3 adrenergic receptors specifically in the bladder muscle, allowing the bladder to relax and hold more urine.

It was first approved by the FDA in June 2012 under the brand name Myrbetriq, made by Astellas Pharma. It comes in 25 mg and 50 mg extended-release tablets and is taken once daily. Patients typically start at 25 mg and increase to 50 mg after 4 to 8 weeks if needed.

Is There an Official Mirabegron XR Shortage in 2026?

As of 2026, Mirabegron XR is not listed on the FDA's official drug shortage database. Brand-name Myrbetriq from Astellas remains generally available at most pharmacies. However, "no official shortage" does not mean every pharmacy near you will have it in stock — and for many patients, the real challenge is not a manufacturing crisis but a complicated mix of legal, insurance, and supply chain factors.

Why Generic Mirabegron Is Hard to Find: Patent Litigation

The bigger access problem in 2026 involves generic mirabegron extended-release. A generic version of Myrbetriq was first approved by the FDA in September 2022 when Lupin Pharmaceuticals received approval after Astellas's key patent expired. Several other manufacturers — including Zydus, Alkem, Aurobindo, and Sawai USA — also received FDA approvals.

However, in April 2025, a federal court issued an injunction blocking two of the largest generic manufacturers — Lupin and Zydus — from selling their generic mirabegron products due to ongoing patent litigation. This suddenly removed two significant suppliers from the market. While Alkem and other manufacturers remain in the market, pharmacy-level availability of generic mirabegron has become inconsistent depending on which suppliers each pharmacy uses.

The practical effect: one CVS may have generic mirabegron in stock while the Walgreens two miles away is completely out. Patients who were previously filling generic mirabegron at a lower cost are now sometimes forced to pay brand-name Myrbetriq prices — or go without.

Insurance Step Therapy Changes: A New Access Barrier in 2025-2026

Beyond the supply side, insurance coverage changes have added another layer of difficulty. Starting in November 2025, major insurers including UnitedHealthcare implemented step therapy requirements for mirabegron. Step therapy — sometimes called a "fail first" policy — means your insurance plan requires you to try and fail on two alternative, lower-cost OAB medications (usually anticholinergics like oxybutynin or tolterodine) before your plan will cover Mirabegron XR.

For patients who are new to OAB treatment, this means Mirabegron XR may not be covered right away even though your doctor prescribed it. For patients already successfully taking Mirabegron XR, being switched to this coverage policy mid-treatment can force difficult conversations with insurers.

38,901+ patients found their medications in stock

38K+

Find Mirabegron XR In Stock Today →

Why Some Pharmacies Have It and Others Don't

Even when there is no declared shortage, local pharmacy availability can be wildly inconsistent for these reasons:

Different pharmacies contract with different wholesale distributors — and different distributors may carry different generic manufacturers.

Smaller independent pharmacies may not routinely stock extended-release mirabegron if demand at their location is low.

With Lupin and Zydus out of the market, pharmacies using those distributors may have gaps until they reorder from Alkem or another manufacturer.

Brand-name Myrbetriq is more consistently available but costs $450 to $625 per month out of pocket without insurance or a savings card.

What Should You Do If You Can't Find Mirabegron XR?

Here are practical steps to take right now:

Call multiple pharmacies — local chains, big box stores, and independent pharmacies. Availability varies widely.

Ask your pharmacist about switching between generic manufacturers. If your pharmacy carries Alkem's generic, it may be in stock even if Lupin's version is not.

Ask about brand-name Myrbetriq with an Astellas Momentum Savings Card, which can reduce out-of-pocket costs for commercially insured patients.

Use GoodRx or SingleCare coupons for generic mirabegron — when available, generic can cost as little as $115 to $212 per month with a coupon.

Talk to your doctor about alternatives if supply continues to be a problem. Vibegron (Gemtesa) is another beta-3 agonist that works similarly to mirabegron. Older antimuscarinic drugs like solifenacin (Vesicare) or tolterodine (Detrol LA) are also options.

Skip the calls, skip the stress.

Find Mirabegron XR In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

How medfinder Can Help

Calling pharmacy after pharmacy is exhausting — especially when you just want to fill your prescription and get on with your life. medfinder is a paid service that calls pharmacies near you on your behalf to check which ones currently have Mirabegron XR in stock. You provide your medication details and zip code, and medfinder texts you the results — no hold music required.

What About Insurance Coverage Issues?

If your insurance has added step therapy requirements, ask your doctor to submit a prior authorization (PA) exception request. They can document why Mirabegron XR is medically necessary for you — especially if you have tried or cannot tolerate anticholinergic medications. Many exceptions are approved.

For the latest updates on availability and what specific changes are affecting coverage, see our 2026 Mirabegron XR shortage update for patients.

The Bottom Line

Mirabegron XR is not in a formal FDA shortage, but 2026 has brought real access challenges: generic supply disruption from patent litigation and new insurance step therapy requirements are the two biggest culprits. Brand-name Myrbetriq remains available, but the cost can be prohibitive without help from savings programs. The good news is that with some persistence — calling pharmacies, using coupons, and involving your prescriber in insurance appeals — most patients can get access to this medication.